As expected, and at this point, immaterial to Merck. But it does build out the COPD franchise appreciably. [With my early July 2025 backgrounder on it, here.]
Here's the official notice (and again, we will be off-grid when it closes); do see here:
. . .On September 24, 2025, Verona Pharma‘s shareholders approved the acquisition by Merck & Co., Inc. through its subsidiary, Vol Holdings LLC, for $107 per American Depository Share, totaling approximately $10 billion.
The transaction, structured as a scheme of arrangement under English law, awaits the High Court of Justice’s sanction, with the effective date expected to be October 7, 2025, pending certain closing conditions. . . .
Now you know. Have a great weekend, one and all!
नमस्ते

No comments:
Post a Comment